BR9917112A - Compostos de imidazol e seu uso medicinal - Google Patents

Compostos de imidazol e seu uso medicinal

Info

Publication number
BR9917112A
BR9917112A BR9917112-0A BR9917112A BR9917112A BR 9917112 A BR9917112 A BR 9917112A BR 9917112 A BR9917112 A BR 9917112A BR 9917112 A BR9917112 A BR 9917112A
Authority
BR
Brazil
Prior art keywords
action
imidazole compounds
medicinal use
smooth muscle
compounds
Prior art date
Application number
BR9917112-0A
Other languages
English (en)
Inventor
Hiroshi Kayakiri
Yoshito Abe
Hitoshi Hamashima
Hitoshi Sawada
Naoki Ishibashi
Hiroyuki Setoi
Teruo Oku
Noritsugu Yamasaki
Takafumi Imoto
Takahiro Hiramura
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of BR9917112A publication Critical patent/BR9917112A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C07D233/92—Nitro radicals attached in position 4 or 5
    • C07D233/94—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS DE IMIDAZOL E SEU USO MEDICINAL". Representados pela fórmula geral (I): onde cada símbolo é conforme definido na especificação, e sais dos mesmos, sendo provida uma composição farmacêutica contendo os mesmos. Esses compostos são úteis no tratamento de doenças curáveis com base numa ação hipoglicêmica, e de doenças curáveis com base numa ação inibidora de cGMP-PDE, numa ação relaxante da musculatura lisa, numa ação broncodilatadora, numa ação vasodilatadora, numa ação inibidora da musculatura lisa e numa ação inibidora de alergia.
BR9917112-0A 1998-12-24 1999-12-20 Compostos de imidazol e seu uso medicinal BR9917112A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP36736298 1998-12-24
JP22883899 1999-08-12
PCT/JP1999/007160 WO2000039097A1 (en) 1998-12-24 1999-12-20 Imidazole compounds and medicinal use thereof

Publications (1)

Publication Number Publication Date
BR9917112A true BR9917112A (pt) 2002-01-29

Family

ID=26528483

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9917112-0A BR9917112A (pt) 1998-12-24 1999-12-20 Compostos de imidazol e seu uso medicinal

Country Status (18)

Country Link
US (1) US7060721B1 (pt)
EP (1) EP1142879B1 (pt)
KR (1) KR20010094731A (pt)
CN (1) CN1170822C (pt)
AR (1) AR022019A1 (pt)
AT (1) ATE375332T1 (pt)
AU (1) AU758325C (pt)
BR (1) BR9917112A (pt)
CA (1) CA2356838A1 (pt)
CZ (1) CZ20012338A3 (pt)
DE (1) DE69937307T2 (pt)
ES (1) ES2292262T3 (pt)
HU (1) HUP0104657A3 (pt)
IL (1) IL143802A0 (pt)
RU (1) RU2238937C2 (pt)
TR (1) TR200101865T2 (pt)
TW (1) TWI239330B (pt)
WO (1) WO2000039097A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009037D0 (en) * 2000-04-13 2000-05-31 Novartis Ag Organic compounds
US20030181461A1 (en) * 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
US7452909B2 (en) * 2003-09-04 2008-11-18 Hoffman-La Roche Inc. Imidazole derivatives
DE102004020186A1 (de) * 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ES2249992B1 (es) * 2004-09-13 2007-03-01 Ferrer Internacional, S.A. Un procedimiento para fabricar compuestos enantiomericos del imidazol.
RU2412943C2 (ru) * 2005-03-23 2011-02-27 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ АЦЕТИЛЕНИЛ-ПИРАЗОЛО-ПИРИМИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGluR2
TW200740435A (en) * 2005-08-10 2007-11-01 Takeda Pharmaceuticals Co Therapeutic agent for diabetes
EP2013186A1 (en) * 2006-04-21 2009-01-14 AstraZeneca AB Imidazole derivatives for use as edg-1 antagonists
RU2439062C2 (ru) * 2006-10-19 2012-01-10 Ф.Хоффманн-Ля Рош Аг Производные имидазолона и имидазолидинона как 11в-hsd1 ингибиторы при диабете
TW200838501A (en) * 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
MX2009008103A (es) * 2007-02-09 2009-08-18 Takeda Pharmaceutical Compuestos anulares fusionados como agonistas parciales de prar-gamma.
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TWI406850B (zh) 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
KR100868898B1 (ko) * 2007-07-30 2008-11-14 한국기계연구원 적층형 ｐｚｔ를 이용한 압전펌프
EP2200975A1 (en) 2007-09-07 2010-06-30 Theravance, Inc. Dual-acting antihypertensive agents
US8212052B2 (en) 2007-12-11 2012-07-03 Theravance, Inc. Dual-acting benzoimidazole antihypertensive agents
JP2011518884A (ja) 2008-04-29 2011-06-30 セラヴァンス， インコーポレーテッド 二重活性抗高血圧剤
US8124636B2 (en) * 2008-04-30 2012-02-28 Hoffmann-La Roche Inc. Imidazolidinone derivatives as 11B-HSD1 inhibitors
US7863309B2 (en) 2008-07-24 2011-01-04 Theravance, Inc. Dual-acting antihypertensive agents
CA2760748A1 (en) * 2009-05-15 2010-11-18 Kai Rossen Process for the preparation of a compound useful as an inhibitor of tafia
WO2011005674A1 (en) 2009-07-07 2011-01-13 Theravance, Inc. Dual-acting pyrazole antihypertensive agents
WO2011011232A1 (en) 2009-07-22 2011-01-27 Theravance, Inc. Dual-acting oxazole antihypertensive agents
US8481549B2 (en) * 2010-01-19 2013-07-09 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
WO2020050241A1 (ja) 2018-09-04 2020-03-12 中外製薬株式会社 ４環性化合物の製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA908300B (en) * 1989-10-24 1992-06-24 Takeda Chemical Industries Ltd Benzimidazole derivatives,their production and use
US5215994A (en) 1990-09-25 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic derivatives
TW235963B (pt) 1992-01-16 1994-12-11 Shionogi & Co
EP0882718B1 (en) 1995-12-28 2005-08-31 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
RU2199532C2 (ru) 1997-06-27 2003-02-27 Фудзисава Фармасьютикал Ко., Лтд. Сульфонамидное соединение
ES2229510T3 (es) 1997-06-27 2005-04-16 Fujisawa Pharmaceutical Co., Ltd. Derivados de anillo aromatico.

Also Published As

Publication number Publication date
CN1335837A (zh) 2002-02-13
AU758325C (en) 2004-10-07
ATE375332T1 (de) 2007-10-15
CA2356838A1 (en) 2000-07-06
HUP0104657A3 (en) 2002-07-29
TR200101865T2 (tr) 2001-12-21
US7060721B1 (en) 2006-06-13
WO2000039097A1 (en) 2000-07-06
AU1690500A (en) 2000-07-31
DE69937307D1 (de) 2007-11-22
EP1142879A4 (en) 2002-02-06
EP1142879B1 (en) 2007-10-10
CZ20012338A3 (cs) 2001-12-12
AR022019A1 (es) 2002-09-04
AU758325B2 (en) 2003-03-20
ES2292262T3 (es) 2008-03-01
TWI239330B (en) 2005-09-11
EP1142879A1 (en) 2001-10-10
HK1043791A1 (en) 2002-09-27
RU2238937C2 (ru) 2004-10-27
HUP0104657A2 (hu) 2002-05-29
CN1170822C (zh) 2004-10-13
KR20010094731A (ko) 2001-11-01
IL143802A0 (en) 2002-04-21
DE69937307T2 (de) 2008-02-07

Similar Documents

Publication Publication Date Title
BR0113757A (pt) Derivados de quinolinona como inibibores de tirosina quinase
ATE330959T1 (de) Allosterische adenosin-rezeptor-modulatore
BR9911779A (pt) Benzotiofenos, benzofuranos e indóis úteis no tratamento de resistência à insulina e hiperglicemia
SE0001899D0 (sv) New compounds
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
BRPI0407882A (pt) conjugados de polìmero-porção de fator viii
BR0215240A (pt) Derivados de calcona e seu uso no tratamento de doenças
BR0115446A (pt) Processos para tratamento de condições associadas a quinase p38 e compostos pirrolotriazina úteis como inibidores de quinase
MA27040A1 (fr) Nucleosides substitues en 4'
SE9504661D0 (sv) New compounds
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
BR0109336A (pt) Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
BR0008840A (pt) Derivados de camptotecina tendo atividade antitumoral
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
ATE527254T1 (de) Mit imidazol enthaltenden sekundären aminen substituierte benzopyran-derivate, deren herstellung und diese enthaltende pharmazeutische zubereitungen
ES2170813T3 (es) Acidos 2,2-dicloroalcanocarboxilicos, proceso para su preparacion, medicamentos que los contienen y su uso para tratar la resistencia a la insulina.
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TR200101865T2 (tr) İmidazol bileşimleri ve onların tıbbi kullanımları.
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
SE9802208D0 (sv) Novel compounds
Chleboun et al. Skeletal muscle architecture and fiber-type distribution with the multiple bellies of the mouse extensor digitorum longus muscle
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
NO893135D0 (no) Fremgangsmaate for fremstilling av n-2,3-butadienyl tri- og tetraaminoalkanderivater.
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
NZ324380A (en) Therapeutic benzimidazole compounds and their use in treatment of virus infections

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP)

Free format text: TRANSFERIDO POR FUSAO DE: FUJISAWA PHARMACEUTICAL CO., LTD.

B25D Requested change of name of applicant approved

Owner name: ASTELLAS PHARMA INC. (JP)

Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 1986 DE 27/03/2009.